Large hemizygous deletions are found in most tumors and might be both hallmarks and drivers of cancer 1 . Hemizygous segmental chromosomal deletions are also frequent in normal genomes 2 . Apart from rare prototypic deletion syndromes (e.g., Smith-Magenis, Williams-Beuren, 22q11 deletion syndromes), genome-wide association studies (GWAS) have implicated genomic deletions in neurodevelopmental diseases like schizophrenia and autism 3 , prompting the hypothesis that deletions might account for an important source of the 'missing heritability' of complex diseases 3, 4 .
A R T I C L E S
Large hemizygous deletions are found in most tumors and might be both hallmarks and drivers of cancer 1 . Hemizygous segmental chromosomal deletions are also frequent in normal genomes 2 . Apart from rare prototypic deletion syndromes (e.g., Smith-Magenis, Williams-Beuren, 22q11 deletion syndromes), genome-wide association studies (GWAS) have implicated genomic deletions in neurodevelopmental diseases like schizophrenia and autism 3 , prompting the hypothesis that deletions might account for an important source of the 'missing heritability' of complex diseases 3, 4 .
Unlike translocations or point mutations, chromosomal deletions are difficult to study with existing tools because primary patient material is often scarce, and incomplete conservation of synteny (homologous genetic loci can be present on different chromosomes or in different physical locations relative to each other within a chromosome across species) complicate modeling in mice. Dissecting the role of specific chromosomal deletions in specific cancers entails, first, determining if a deletion has phenotypic consequences; second, determining if the mechanism fits a "classic" recessive (satisfying Knudson's "twohit" hypothesis) or a haploinsufficiency model and, finally, identifying the specific genetic elements that are lost. Classic tumor suppressor genes were discovered through physical mapping of homozygous deletions 5 . More recent data suggest that sporadic tumor suppressor genes are more likely to be mono-allelically lost and to function through haploinsufficiency (wherein a single functional copy of a gene is insufficient to maintain normal function) 6, 7 .
MDS are clonal hematologic disorders characterized by ineffective hematopoiesis and a propensity for progression to acute myeloid leukemia (AML) 8 . Somatic loss of one copy of the long arm of chromosome 7 (del(7q)) is a characteristic cytogenetic abnormality in MDS, well-recognized for decades as a marker of unfavorable prognosis. However, the role of del(7q) in the pathogenesis of MDS remains elusive. The deletions are typically large and dispersed along the entire long arm of chr7 (ref. 9) . Homology for human chr7q maps to four different mouse chromosomes.
Functional analysis of a chromosomal deletion associated with myelodysplastic syndromes using isogenic human induced pluripotent stem cells Chromosomal deletions associated with human diseases, such as cancer, are common, but synteny issues complicate modeling of these deletions in mice. We use cellular reprogramming and genome engineering to functionally dissect the loss of chromosome 7q (del(7q)), a somatic cytogenetic abnormality present in myelodysplastic syndromes (MDS). We derive del(7q)-and isogenic karyotypically normal induced pluripotent stem cells (iPSCs) from hematopoietic cells of MDS patients and show that the del(7q) iPSCs recapitulate disease-associated phenotypes, including impaired hematopoietic differentiation. These disease phenotypes are rescued by spontaneous dosage correction and can be reproduced in karyotypically normal cells by engineering hemizygosity of defined chr7q segments in a 20-Mb region. We use a phenotype-rescue screen to identify candidate haploinsufficient genes that might mediate the del(7q)-hematopoietic defect. Our approach highlights the utility of human iPSCs both for functional mapping of disease-associated large-scale chromosomal deletions and for discovery of haploinsufficient genes.
Genetic engineering of human pluripotent stem cells (hPSCs) has been used to model point mutations causing monogenic diseases in an isogenic setting 10, 11 , but not disease-associated genomic deletions. We used reprogramming and chromosome engineering to model del(7q) in an isogenic setting in hPSCs. Using different isogenic pairs of hPSCs harboring one or two copies of chr7q, we characterized hematopoietic defects mediated by del(7q). We used spontaneous rescue and genome editing experiments to show that these phenotypes are mediated by a haploid dose of chr7q material, consistent with haploinsufficiency of one or more genes. We functionally map a 20-Mb fragment spanning cytobands 7q32.3-7q36.1 as the crucial region and identify candidate disease-specific haploinsufficient genes using a phenotype-rescue screen. Finally, we show that the hematopoietic defect is mediated by the combined haploinsufficiency of EZH2, in cooperation with one or more out of three additional candidate genes residing in this region. The strategy reported here could be applied to study the phenotypic consequences of segmental chromosomal deletions and for haploinsufficient gene discovery in a variety of human cancers, and neurological and developmental diseases.
RESULTS

Generation of del(7q)-and normal isogenic iPSCs
We derived iPSC lines from hematopoietic cells of two patients (patients no. 2 and no. 3) with del(7q)-MDS ( Fig. 1 and Supplementary Tables 1 and 2). We reasoned that residual normal hematopoietic cells are likely to co-exist with the MDS clone in the bone marrow of MDS patients and that we could exploit this to reprogram both del(7q)-and isogenic karyotypically normal cells in parallel. We were able to derive del(7q)-and karyotypically normal (N-) iPSC lines at the same reprogramming round from both patients (Supplementary Table 3) . We used an excisable lentiviral vector expressing OCT4 (also known as POU5F1), KLF4, c-MYC (also known as MYCBP) and SOX2 for reprogramming 12, 13 and performed vector integration analysis to exclude iPSC lines derived from the same starting cell from being considered independent lines and thus obtain true biological replicate lines from each patient (Supplementary Fig. 1a,b) . Karyotyping showed that the iPSC lines harbored identical deletions to those present in the starting patient cells (Fig. 1c) , which we mapped by array-based comparative genomic hybridization (aCGH) (Fig. 1d) . These iPSC lines met all standard criteria of pluripotency, before and after excision of the reprogramming vector, including expression of pluripotency markers, demethylation of the OCT4 promoter and formation of trilineage teratomas after injection into immunodeficient mice ( Fig. 1b and  Supplementary Fig. 1c-f) . We selected from patients no. 2 and no. 3, respectively, two and three del(7q)-iPSC lines (MDS-2.13, MDS-2.A3, MDS-3.1, MDS-3.4, MDS-3.5), as well as four and one karyotypically normal iPSC line (N-2.8, N-2.12, N-2.A2, N-2.A11, N-3.10) before or after vector excision, for further studies (Supplementary Table 1) .
Recent large-scale sequencing studies have shown that MDS undergoes genetic evolution through multiple cycles of mutation acquisition 14 . To determine whether the karyotypically normal iPSC lines originate from a completely normal hematopoietic cell or from a potential 'founding' clone harboring mutations that might have arisen before the del(7q), we performed whole exome sequencing of bone marrow mononuclear cells (BMMCs) and fibroblasts (as paired normal sample) from MDS patient no. 2, as well as of one del(7q)-and one normal iPSC line derived from BMMCs of this patient (MDS-2.13 and N-2.12, respectively) and identified the somatic variants. Thirty-four single-nucleotide variants (SNVs) were identified with confidence in the BMMCs by comparison to the fibroblast sample, after filtering out intronic variants, variants with less than 30 reads in BMMCs and fibroblasts, and variants with variant allele frequency >1% in fibroblasts or <10% in BMMCs ( Fig. 1e and Supplementary  Table 4) . Similarly, 73 and 48 somatic SNVs were identified in the del(7q)-and isogenic normal iPSC line, respectively. The del(7q)-iPSC line contained all 34 variants of the MDS clone, whereas the isogenic normal line harbored none. These variants included two genes found recurrently mutated in MDS, SRSF2 and PHF6. Resequencing of the rest of the iPSC lines derived from this patient ( Supplementary  Table 2 ) showed that all of the del(7q)-(6 out of 6) and none of the karyotypically normal iPSC lines (0 out of 15) harbored these mutations. These results unequivocally demonstrate that the isogenic iPSCs represent normal cells that contain no premalignant lesions and that the del(7q)-iPSCs accurately capture the genetic composition of the MDS clone.
Decreased hematopoietic differentiation of del(7q)-MDS iPSCs
To assess the hematopoietic differentiation potential of the MDS iPSCs we optimized an embryoid body-based differentiation protocol and monitored the course of differentiation using CD34, a hemato-endothelial marker, and CD45, the key marker of definitive hematopoietic cells 15 . In this differentiation protocol, normal human embryonic stem cell (hESC) and iPSC lines typically express CD34 by day 6. Co-expression of CD45 appears by day 10, peaks at day 14, and is followed by loss of CD34, as the cells become more differentiated along hematopoietic lineages. By day 18, typically more than 90% of cells are CD45 + (Supplementary Fig. 2a) . We assessed the intra-( Supplementary Fig. 2a,b , panels I, II and c) and inter- (Supplementary Fig. 2a,b , panels III, IV) line variation in this differentiation process using normal iPSC lines derived from bone marrow cells of patients no. 2 and no. 3, as well as one additional iPSC line derived previously from umbilical cord blood CD34 + cells, CB-3.1-Cre (ref. 13 ). On day 10 we observed some interexperimental variation in expression of CD34 and CD45 markers, whereas little variation was present on day 14 and even less on day 18. Notably, increasing passage number did not alter the differentiation potential ( Supplementary Fig. 2a,b , panel II) and distinct iPSC lines derived from the same individual (in the same or different reprogramming experiments) exhibited variation similar to the intra-line variation ( Supplementary Fig. 2a,b , compare panels II and III) and substantially lower than that seen in iPSC lines derived from different genetic backgrounds on day 14 ( Supplementary Fig. 2a,b , compare panels III and IV). These results show that different genetic background is the main source of variation and that variation among different lines from the same individual is no greater than the intra-line variation.
Having established the reproducibility and range of normal variation in the hematopoietic differentiation of normal iPSCs, we then tested the hematopoietic potential of MDS iPSCs. All MDS-iPSC lines exhibited greatly reduced hematopoietic differentiation potential ( Fig. 2a) and clonogenic capacity ( Fig. 2b and Supplementary  Fig. 3a ) affecting all myeloid hematopoietic lineages (Fig. 2c) . The MDS-iPSC lines also showed increased cell death during differentiation compared to their isogenic and nonisogenic normal iPSC lines ( Fig. 2d and Supplementary Fig. 3b) . In addition to an absolute decrease in the efficiency of differentiation, MDS-iPSC lines differentiated with slower kinetics (Supplementary Fig. 3c,f) . This observation was corroborated by assessing the kinetics of the emergence and disappearance of a transient wave or primitive-like hematopoiesis, marked by co-expression of CD41a and CD235 (glycophorin A; GPA) 16 (Supplementary Fig. 3d,e) . Furthermore, upon differentiation along the erythroid lineage, MDS-iPSC lines, unlike their normal isogenic lines, did not acquire cell-surface markers or morphological npg features of erythroid cells ( Fig. 2e and Supplementary Fig. 3g,h ). These phenotypes of ineffective hematopoiesis, reduced or absent clonogenicity, and increased cell death are consistent with the phenotype of ex vivo cultured primary MDS cells from bone marrow or peripheral blood 17, 18 .
MDS-iPSC hematopoiesis rescue by chr7q dosage correction
Apart from the profound hematopoietic defects, at least some of the MDS-iPSC lines exhibited slower growth in culture at the undifferentiated state compared to their isogenic normal iPSCs, as observed by smaller colony size (Supplementary Fig. 4a ) and confirmed by growth competition assays against a GFP-marked normal iPSC line derived from N-2.12 ( Supplementary Fig. 4b,c) . Because hPSCs can spontaneously acquire chromosomal abnormalities and those that provide a growth advantage can be selected over time in culture (as the clone that harbors them outgrows the rest of the population), we reasoned that we might be able to isolate clones that spontaneously acquired a second copy of chr7q material. Indeed, by screening additional iPSC lines derived from patient no. 3 for chr7q dosage using a qPCR assay, we identified one line, MDS-3.9, that had acquired an additional chromosome 7, an event not detectable in the starting bone marrow cells (Fig. 3a) . Additionally, by monitoring chr7q dosage in the del(7q)-MDS iPSC lines over time, we were able to detect spontaneous dosage correction in one del(7q)-MDS iPSC line derived from patient no. 2, MDS-2.13, at passage 40 (Fig. 3b) . We excluded the possibility of contamination of the culture with an unrelated line by reprogramming There is no overlap between the MDS clone variants and the variants found in the normal isogenic line, demonstrating that the latter is derived from a normal residual hematopoietic cell that is unrelated to the cell that gave rise to the MDS clone. npg vector integration analysis (Fig. 3c) . Karyotyping and aCGH showed that dosage correction had again occurred through duplication of the normal intact chromosome 7 (Fig. 3d,e) . As expected, the derivative line MDS-2.13C grew faster than its parental line in subsequent culture, albeit not as fast as its isogenic karyotypically normal iPSCs ( Supplementary Fig. 4d ). The same phenomenon of spontaneous acquisition of an extra chromosome 7 occurred in two additional independent clones of the same iPSC line, obtained after single-cell subcloning of early-passage cells (before or after reprogramming vector excision), selection of a chr7q haploid clone and subsequent expansion for more than ten passages. Notably, a large chromosome 3q deletion also initially present in this iPSC line (and in the patient bone marrow cells it was derived from) remained unchanged ( Figs. 1c and 3d) . Moreover, we never observed acquisition of extra chr7 copies in normal iPSC lines by close qPCR monitoring over more than 50 passages, in line with reports from systematic studies of chromosomal aberrations commonly observed in hPSCs 19, 20 .
These events of spontaneous compensation of chr7q dosage imbalance provided evidence for strong in vitro selection for these events. We therefore screened additional del(7q)-MDS iPSC lines using more probes along the length of chr7 to potentially find clones with duplications of only part of chr7q. We were able to identify an informative clone derived from a second del(7q)-iPSC line from patient 2, MDS-2.A3, which over time acquired a second copy of a telomeric part of chr7q without duplication of the entire chr7 (Fig. 3f,g ). aCGH analysis showed that the duplicated region was approximately 30 Mb and spanned bands 7q32.3-7qter ( Fig. 3h and Supplementary Table 5 ). The hematopoietic differentiation potential of this 'corrected' line, MDS-2.A3C, was fully restored to levels comparable to those of normal iPSCs (Fig. 3i,j) . The corrected line maintained the SRSF2 and PHF6 mutations. These data strongly suggest that reduced chr7q dosage is responsible for the hematopoietic defect of MDS iPSCs, as the latter is fully rescued by acquisition of a second copy of chr7q material derived from duplication of the existing copy, and pinpoint 
Engineering heterozygous chr7q loss in normal hPSCs
To further determine the impact of chr7q hemizygosity on the cellular phenotype, we generated perfectly isogenic pairs of hPSCs harboring one or two copies of chr7q by engineering chr7q deletions in normal hPSCs. To this end, we combined a recently reported strategy for deleting supernumerary chromosomes using adeno-associated vector (AAV)-mediated gene targeting of an HSV-tk transgene 21 with a previously described strategy using Cre-mediated recombination of inverted loxP sites 22, 23 (Fig. 4a) . We constructed an AAV vector containing two loxP sites in inverted orientation and a positive (puro) and negative (HSV-tk) selection marker. The vector was targeted to a near-telomeric region of chromosome 7 (7q36.3) by ATG-trap of the DNAJB6 gene, highly expressed in hPSCs (Supplementary Fig. 5a ).
The hESC line H1, as well as the normal iPSC line N-2.12, were transduced with the vector. Fourteen and five puromycin-resistant clones from line N-2.12 and H1, respectively, were picked, initially screened by PCR specific for the targeted allele and subsequently by Southern blot analysis (Supplementary Fig. 5b) . Thirteen of the 14 N-2.12 clones were found to be correctly targeted and one to have a random vector integration. Fig. 5c ). aCGH showed that these clones harbored different deletions spanning variable lengths along the entire chromosome 7q ( Fig. 4b and Supplementary Table 6 ). Clones N-2.12-D-Cre-44 and N-2.12-D-6Cre6 were among the selected ganciclovir-resistant clones, although the chr7q deletion in these clones does not include the tk gene. Ganciclovir resistance may have been conferred by a mutation or other mechanisms. Clones N-2.12-D-Cre10 and N-2.12-D-Cre32 shared the exact same deletion and hence were presumably derived from the same clone, but were treated as separate clones. Based on our previous phenotypic characterization data ( Fig. 2 and  Supplementary Fig. 2) , we selected the percentage of CD45 + cells at day 14 of hematopoietic differentiation as the most appropriate readout. Eight of the ten clones showed markedly diminished hematopoietic differentiation potential and clonogenic capacity (Fig. 4c-e) , similarly to our del(7q)-MDS iPSCs. Notably, two of the seven clones (Fig. 4c-e) . The chr7q region that these two clones, but none of the other eight clones, maintained in a diploid dosage was a ~40 Mb region spanning 7q31.1-q36.1 (Fig. 4f) , which shared ~20 Mb of overlap with the region acquired by the 'rescued' MDS-2.A3C clone (Fig. 3h) . The phenotypic analysis of our collection of engineered del(7q)-hESC and iPSC clones, in combination with our findings in the spontaneously corrected line MDS-2.A3C, functionally delineate a ~20 Mb region, spanning 7q32.3-7q36.1 (nucleotides approximately 131,706,336-152,127,281), as the critical region in del(7q)-MDS (Fig. 4f) .
Phenotype-rescue screen of chr7q genes Our data provide functional evidence that chr7q hemizygosity mediates MDS phenotypes through a dosage effect, as these phenotypes are rescued by acquisition of a duplicated copy of chr7q material and recapitulated by the artificial engineering of hemizygosity in normal cells. Indeed, gene expression analyses in our isogenic iPSC pairs show that hemizygosity of chr7q results in reduced expression levels of a large number of genes in the chr7q deleted region, which are restored upon chr7q dosage correction ( Supplementary  Fig. 6 ). There is increasing evidence that cancer-associated deletions may produce collective phenotypes through the cumulative haploinsufficiencies of multiple genes that opportunistically colocalize in the deleted clusters 7, 24, 25 . It is therefore likely that the del(7q) mediates multiple gene haploinsufficiencies that cooperate in producing the hematopoietic phenotype, similarly to what was shown in del(5q)-MDS 26, 27 . To identify candidate haploinsufficient genes in chr7q (whose reduction in dosage from two copies to one is expected to result in a substantial reduction in expression and function), we selected genes with significantly reduced expression at the haploid state by analyzing two pairs of isogenic iPSCs harboring one or two copies of chr7q, derived through reprogramming (MDS-2.13 vs N-2.12) and through spontaneous correction (MDS-2.13 vs MDS-2.13C). 105 and 94 genes, respectively, were found to be reduced by at least 1.5-fold (log 2 (FC) ≥ 0.585), 64 of which were found in both comparisons ( Fig. 5a and Supplementary Table 7) . Prioritizing these 64 genes, as well as genes with the highest differences in expression, and after excluding genes with very low expression in human HSPCs 28 , we selected 62 genes and constructed a lentiviral open reading frame (ORF) library with each ORF tagged to a unique 4-nucleotide barcode sequence (Supplementary Fig. 7a-c and Supplementary Table 9 ). To maximize the chance that a gene will present as a hit, we performed multiple independent transductions at a high multiplicity of infection (MOI). 
npg
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To assess representation of all vectors and barcodes and test for potential biases introduced by sample preparation, we performed high-throughput sequencing of the barcodes in two samples derived from the same transduced cell pool (transduction no. 4) processed independently from collection to sequencing. This analysis showed representation of all the barcodes included in the transduced library batch (batch no. 1), which was practically identical between the two separately processed samples (Supplementary Table 10 and Supplementary Fig. 7d ). The transduced cell pools were monitored weekly for vector silencing (by flow cytometry for GFP) and for spontaneous chr7q duplication by chr7q copy number qPCR. Experiments where GFP expression became undetectable soon after transduction or where chr7q copy number became >1.5 were discontinued (transductions no. 1, no. 4 and no. 5, Supplementary Table 9) . For each screening experiment, transduced del(7q)-iPSCs were differentiated along the hematopoietic lineage, CD45 + cells were sorted on day 15 of differentiation, and paired samples of the sorted CD45 + cells and the starting undifferentiated cells were subjected to high-throughput sequencing of the barcodes ( Supplementary  Fig. 7a) . A total of eight screening experiments in six independently transduced cell pools from the two del(7q)-iPSC lines were done and enrichment in CD45 + hematopoietic progenitors relative to undifferentiated cells was calculated for each ORF and barcode ( Fig. 5b and Supplementary Table 11 ). Focusing on hits residing in the critical region 7q32.3-7q36.1, identified above, ten genes were found enriched (by >1.5-fold) recurrently (i.e., in at least two independent experiments) ( Supplementary Fig. 7e and Supplementary  Table 11 ). These were LUC7L2, HIPK2, MRPS33, ADCK2, SSBP1, AGK, EZH2, ATP6V0E2, NUB1 and GALNT11. Six of them (LUC7L2, HIPK2, ADCK2, EZH2, ATP6V0E2 and GALNT11) presented as hits in more than half of the experiments they were tested in and were considered as 'stronger' hits. These six genes, as well as two of the four remaining hits (SSBP1 and AGK) were individually tested for rescue of hematopoiesis in a different del(7q)-iPSC line than the ones used SLC25A13  SHFM1  BRI3  ARPC1A  BUD31  PTCD1  CPSF4  ATP5J2  MCM7  PPP1R35  POP7  SLC12A9  TRIP6  TRIM56  AP1S1  PLOD3  ZNHIT1  CLDN15  FIS1  EMID2  LRWD1  POLR2J3  ARMC10  PMPCB  PSMC2  PSMC2  ORC5L  PUS7  SYPL1  NAMPT npg for the primary screen (Fig. 5c,d and Supplementary Fig. 8a,b) . Four genes, all included among the stronger hits, could be confirmed to partially rescue the emergence of CD45 + hematopoietic progenitors when overexpressed in del(7q)-iPSCs (Fig. 5c,d ). These were HIPK2, ATP6V0E2, LUC7L2 and EZH2.
Validation of chr7q haploinsufficient genes
These four hits were further tested in short hairpin RNA (shRNA) knockdown experiments in normal cord blood (CB) CD34 + hematopoietic progenitors. Different shRNAs were tested and those that conferred a reduction in expression of approximately 50% on average upon transduction of nearly 100% of the cells were selected to approximate haploinsufficiency (Fig. 6a and Supplementary Fig. 9a,b) . Knockdown of each of the four genes reduced colony formation, affecting primarily multipotent and erythroid progenitors rather than more mature myeloid precursors (Fig. 6b) . In vitro expansion and differentiation of erythroblasts were also diminished ( Fig. 6c  and Supplementary Fig. 9c) . Thus, all four confirmed hits could be validated by knockdown assays to diminish hematopoietic potential when knocked down to approximately half of their normal levels.
One of the four hits, EZH2, is a gene encoding a histone methyltransferase that constitutes the catalytic unit of the polycomb repressive complex 2 (PRC2) and is found recurrently mutated in MDS [29] [30] [31] [32] . EZH2 mutations found in MDS are commonly loss-of-function heterozygous mutations, consistent with a haploinsufficiency mechanism 8, 33 . EZH2 expression was reduced but not abolished in our del(7q)-MDS iPSCs (Supplementary Fig. 8d ) and we found no mutations in the second allele. We thus selected EZH2 to validate further. First, we confirmed that restoring EZH2 expression in two additional del(7q)-iPSC lines (MDS-2.13 and N-2.12-D-2Cre4) by lentiviral transduction again partially rescued their hematopoietic differentiation potential (Supplementary Fig. 8c-i) . To further characterize the effect of EZH2 haploinsufficiency in the hematopoietic phenotype, we designed a CRISPR-Cas9-based strategy to inactivate the EZH2 gene in hESCs, by mediating a double-strand break downstream of the ATG and exploiting the error-prone nonhomologous end-joining repair mechanism to introduce frame-shifting insertions or deletions of a few nucleotides (indels) (Fig. 6d) . The hESC line, iCas9-HUES8, carrying an inducible Cas9 transgene inserted into the AAVS1 locus 34 , was transduced with a lentiviral vector expressing a guide RNA (gRNA) targeting EZH2, and clones with mono-allelic indels were isolated ( Fig. 6e and Supplementary Fig. 10a,b) . Two clones (clones 31 and 37), each harboring a different frame-shifting deletion (Fig. 6f) , found to express EZH2 protein at approximately 50% of the normal level (Fig. 6g) and to be clonal ( Supplementary  Fig. 10c ) were selected. The hematopoietic differentiation and colony formation potential of both EZH2 haploinsufficient clones was substantially diminished at levels intermediate between those 
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of normal and del(7q)-iPSCs (Fig. 6h, Supplementary Fig. 10d ,e and compare to Fig. 4c-e) . This is consistent with the partial phenotypic rescue mediated by restoration of EZH2 expression in del(7q)-iPSCs (Fig. 5c,d and Supplementary Fig. 8 ) and supports a model of cooperation between haploinsufficiencies of more than one gene to generate the del(7q) hematopoietic phenotype. In summary, these data show that haploinsufficiency of EZH2 decreases the hematopoietic potential of cells, and that the hematopoietic defects caused by chr7q hemizygosity are mediated through the haploinsufficiency of EZH2, in combination with one or more additional genes, which might include LUC7L2, HIPK2 and/or ATP6V0E2 and possibly additional genes.
DISCUSSION
We used cellular reprogramming for the first time, to our knowledge, to model a somatically acquired genetic lesion in an isogenic human setting, by exploiting the somatic mosaicism in the hematopoietic compartment of MDS patients. Our detailed characterization of a panel of normal isogenic and nonisogenic iPSC lines (Supplementary Fig. 2) , showing that the genetic background is the major source of line-toline variation in differentiation potential, highlights the advantage of using isogenic controls. The efficiency of reprogramming of MDS hematopoietic cells was highly variable between the two patient samples compared to that of isogenic normal cells (Supplementary Table 2 ). It is likely that clonal or subclonal gene mutations increase or diminish reprogramming "fitness" 35 . As reprogramming is an inherently clonal process and can "capture" genetic lesions present at low frequency in the tissue of origin 36 , reprogramming MDS cells could provide a powerful tool to dissect the clonal architecture and evolution of this disease and to link genotypes to cellular phenotypes 14, 37 . Further dissecting the MDS-iPSC phenotypes at the molecular level could provide insights into the pathogenesis of myelodysplasia and leukemic transformation. Moreover, the robustness of our cellular MDS phenotypes could provide a platform for phenotype-driven drug screens to identify small molecules that ameliorate these phenotypes. Our 20-Mb region coincides with some proposed commonly deleted regions from patient studies, but not with others 9, 38, 39 . Among other candidate haploinsufficient genes on chr7q, MLL3 (ref. 40 ) is located inside our critical region, but it was not differentially expressed between del(7q)-and isogenic normal iPSCs in our analysis and therefore not included in our library screen (Supplementary Table 7) . Clearly, additional work is needed for a more complete understanding of the chr7q genetic elements critically involved in del(7q)-MDS and to this end our model can provide a powerful platform for gene complementation assays, as we describe here.
We combined and extended previous strategies to develop a method for introducing large-scale chromosomal deletions (of Mb range) in normal human cells. Previous studies using recombination between inverted loxP sites obtained loss of entire chromosomes rather than segmental deletions 22, 23 . In contrast, we did not find clones with complete monosomy 7. As previous studies attempted to eliminate only supernumerary or sex chromosomes, the different outcome in our study likely reflects incompatibility of the complete loss of an autosome by normal diploid iPSCs with growth in culture. Our methods for engineering deletions can enable studies of the functional consequences of alterations in gene copy number, so far feasible mostly in yeast, for the first time in human cells 41 and may unveil speciesspecific dosage sensitivities that may not manifest themselves in mice or other model organisms 3 . Furthermore, hPSCs with chromosomal deletions can provide a haploid background for engineering complete gene knockouts (by inactivating the remaining allele) or for highthroughput classical forward genetics mutagenesis screens 42 .
Our 'functional mapping' approach could complement genetic mapping and physical mapping approaches, providing a framework to study commonly deleted chromosomal regions of interest. Any cancer or other disease in which a deletion is suspected to be pathogenetic could be modeled with this approach. Somatic mosaicism, if present, as in all cancers and for deletions arising de novo during late stages of development, provides the opportunity to derive isogenic diseased and normal iPSCs directly through reprogramming from the same individual, as we show here. For germline deletions, isogenic controls can be derived only through chromosome engineering approaches.
Gene haploinsufficiency is increasingly appreciated as an important mechanism of phenotypic variation and disease 24, 43, 44 . Genes whose function is dependent on dosage cannot be revealed by genomic approaches and require functional assays. Among the latter, gainof-function (rescue) assays, as we present here, provide substantial advantages over knockdown/knockout screens. We thus envision a generalizable approach to the discovery of haploinsufficient genes starting with genomic data pointing to commonly deleted regions from copy number variant (CNV) databases or cancer genomes (as indicators of mono-allelic loss of function), following a workflow similar to the one we propose here: generate isogenic hPSCs harboring the specific deletion, determine a phenotype in a disease-relevant cell type derived from hPSCs, identify candidate haploinsufficient genes based on their differential expression in the diploid versus haploid state and filter them through phenotype-rescue screens to finally select one or a few candidates for follow-up studies. Because a gene can be mono-allelically inactivated in different ways, our approach can be integrated with data on different classes of mutations (CNVs, singlenucleotide polymorphisms (SNPs)) from cancer genome databases to inform gene prioritization. Indeed, two of the haploinsufficient genes identified in our study, EZH2 and LUC7L2, also harbor recurrent inactivating mutations in MDS and AML genomes 8, 33, 45, 46 .
In summary, we present a strategy for functional cancer genetics that should prove generally applicable to the study of diseaseassociated chromosomal deletions.
METhODS
Methods and any associated references are available in the online version of the paper. Accession codes. Gene expression profiling data are available at GEO: GSE65215. aCGH data are available at GEO: GSE65386 and GSE65387. 
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ONLINE METhODS iPSC generation. Cryopreserved bone marrow or peripheral blood mononuclear cells were thawed and cultured in X-VIVO 15 media with 1% nonessential amino acids (NEAA), 1 mM l-glutamine and 0.1 mM β-mercaptoethanol (2ME) and supplemented with 100 ng/ml stem cell factor (SCF), 100 ng/ml Flt3 ligand (Flt3L), 100 ng/ml thrombopoietin (TPO) and 20 ng/ml IL-3 for 1-4 days. The excisable lentiviral vector CMV-fSV2A expressing OCT4, KLF4, c-MYC and SOX2 (derived from pLM-fSV2A 12 after replacing CMV for hPGK) was used and produced as described 13 . For induction of reprogramming, 10,000-250,000 cells were plated on retronectin-coated 24-well dishes and transduced at an MOI of 30 or higher for 16 h. Two days later, the cells were harvested and plated on mitotically inactivated MEFs (GlobalStem) in 6-well plates and the plates were centrifuged at 500g for 30 min at room temperature. The next day and every day thereafter, half of the medium was changed to hESC medium with 0.5 mM valproic acid. Colonies with hPSC morphology were manually picked and expanded, as described 13 .
Culture of hPSCs on MEFs or in feeder-free conditions was performed as previously described 13 . Characterization of pluripotency (flow cytometry, OCT4 promoter methylation analysis, teratoma formation assays) and Cre-mediated vector excision were done as previously described 12, 13, 47 Whole exome sequencing and calling of somatic variants. Exome sequencing was performed at the University of Washington. Library construction, exome capture, sequencing and mapping were performed as previously described 48 . Briefly, 1 µg of genomic DNA was subjected to a series of shotgun library construction steps, including fragmentation through acoustic sonication (Covaris), end-polishing and A-tailing, ligation of sequencing adaptors and PCR amplification with 8 bp barcodes for multiplexing. Libraries underwent exome capture using the Roche/Nimblegen SeqCap EZ v3.0 (~62 MB target). Prior to sequencing, the library concentration was determined by triplicate qPCR and molecular weight distributions verified on the Agilent Bioanalyzer (consistently 250 ± 25 bp). Sequencing reads were processed through a pipeline consisting of a combined suite of Illumina software and other industry standard software packages (i.e., Genome Analysis ToolKit [GATK], Picard, BWA, SAMTools and in-house custom scripts) that included base calling, alignment, local realignment, duplicate removal, quality recalibration, data merging, variant detection, genotyping and annotation. Somatic variant calling was performed using the MuTect method 49 .
Hematopoietic differentiation. iPSC colonies were collected with dispase and plated in low-attachment dishes in DMEM with 20% FBS, 1% NEAA, 1 mM l-glutamine and 0.1 mM 2ME, supplemented with 30 ng/ml bone morphogenetic protein 4 (BMP4) and 50 µg/ml ascorbic acid. One day later, the medium was switched to StemPro-34 SFM (Gibco) with 1% NEAA, 1 mM l-glutamine and 0.1 mM 2ME supplemented with 30 ng/ml BMP4, 50 ng/ml FGF2 and 50 µg/ml ascorbic acid. At day 4, the cytokine cocktail was changed to: 20 ng/ml vascular endothelial growth factor (VEGF), 10 ng/ml FGF2, 100 ng/ml stem cell factor (SCF), 20 ng/ml Flt3 ligand (Flt3L), 20 ng/ml thrombopoietin (TPO), 40 ng/ml IL-3 and 50 µg/ml ascorbic acid and replaced at day 6. At day 8 the cytokine cocktail was changed to: 100 ng/ml stem cell factor (SCF), 20 ng/ml Flt3 ligand (Flt3L), 20 ng/ml thrombopoietin (TPO), 40 ng/ml IL-3 and 50 µg/ml ascorbic acid and replaced every 2 days. At the end of the embryoid body differentiation culture (day 10, 14 or 18) cells were dissociated with accutase into single cells. For flow cytometry, the following antibodies were used: CD34-PE (clone 563, BD Pharmingen) or CD34-Brilliant Violet 421 (clone 581, BD Pharmingen), CD45-PerCP (clone HI30, Biolegend), CD45-APC (clone HI30, BD Pharmingen), CD43-APC (clone 1G10, BD Pharmingen), CD235a-PE-Cy5 (clone GA-R2, BD Pharmingen) or CD235a-RPE (clone JC159, Dako), CD71-APC (clone M-A712, BD Pharmingen), CD41a-APC-H7 (clone HIP8, BD Pharmingen) and CD33-PE-CF594 (clone WM53, BD Pharmingen). For methylcellulose assays, the cells were resuspended in StemPro-34 SFM medium at a concentration of 3 × 10 4 /ml. 500 µl of cell suspension were mixed with 2.5 ml ColonyGel Human Enriched Complete Medium (ReachBio) and 1 ml was plated in duplicate 35-mm dishes. Colonies were scored after 14 days and averaged between the duplicate dishes. Erythroid differentiation was performed as previously described 12 .
aCGH. aCGH was performed on a chromosome 7-specific array platform (NimbleGen Human CGH 385K Chromosome 7 Tiling Array) with a mean spacing of 365 bp or on a custom array manufactured by Agilent Technologies, consisting of 162,863 unique probes (159,157 on chr7) with a median spacing of 795 bp. Labeling and hybridization were performed according to the manufacturer's instructions. The data set was assessed for quality and median background subtracted signal intensities were normalized using the Bioconductor package limma. The data were further normalized by mean centering the logFC values, where the mean was calculated from all autosomes, except chromosome 7. Aberrations were detected by applying the Genomic Segmentation algorithm (minimum genomic markers: 20; P-value threshold: 0.0001; signalto-noise ratio: 1) within Partek software, version 6.6 (Partek Inc., St. Louis, MO, USA).
Growth assays. For growth curves, 4 × 10 4 cells per well were seeded in triplicate Matrigel-coated 6-well-plates, harvested at different time points and counted on a hemocytometer. Cell counts were calculated relative to the cell count 48 h hours after plating. For growth competition assays, clone N-2.12-GFP was generated by transducing N-2.12 cells with a lentiviral vector expressing eGFP, manually picking a few colonies homogeneously expressing GFP under a fluorescent microscope, expanding them and selecting one with a narrow distribution of GFP expression. iPSCs were mixed 1:1 with the N-2.12-GFP clone and 1 × 10 5 cells/well were plated in triplicate wells of a 6-well plate. One well was harvested the next day (day 1) and the population size of GFP -cells was measured by flow cytometry. Tra-1-81 staining was used to exclude MEFs. The remaining duplicate wells were passaged every 4 days for 16 days, one-third was replated and the rest was used for flow cytometry. The relative population size of GFP -cells at each time point was calculated relative to the population size at day 1.
Cell viability assay. An equal number of cells from each iPSC line was seeded on MEFs in one well of a 6-well plate per time point. Five days later, the cells from each well were harvested separately and induced toward hematopoietic differentiation as described above. On different days, embryoid bodies were collected and treated with accutase to obtain single cells. Cell viability was determined using the CellTiter-Glo Luminescent Cell Viability Assay (Promega) following the manufacturer's instructions. Luminescence was measured on a PerkinElmer Envision Multilabel Detector Plate Reader.
AAV-mediated gene targeting and selection of clones with deletions. The 5′ and 3′ homology arms of the AAV vector consisted of chromosome 7 nucleotides 157,150,063-157,151,258 and 157,151,259-157,152,447 (hg19 human genome assembly), respectively. The entire sequence was amplified from H1 gDNA in two independent PCR reactions, cloned and sequenced, and one allele was chosen for subsequent amplification and cloning. AAV vector production was performed as described 21 . hESCs and iPSCs were transduced in feederfree conditions, replated on puromycin-resistant MEFs and selected with 0.5 µg/ml puromycin for 2-4 days. Southern blot analyses were performed as previously described 13 . Transduction with a Cre-expressing integrase-deficient lentiviral vector was done as previously described 13 . Ganciclovir selection was performed at a concentration of 200 µM for 10-15 days. qPCR for chromosome 7 dosage. TaqMan qPCR was performed as previously described 13 with primers and probes shown in Supplementary Table 12. Gene expression analysis by qRT-PCR. RNA was isolated with Trizol (Life Technologies). Reverse transcription was performed with Superscript III (Life Technologies) and qPCR was performed with the SsoFast EvaGreen Supermix (Bio-Rad) using primers shown in Supplementary Table 13 . Reactions were carried out in triplicate in a 7500 Fast Real-Time PCR System (Applied Biosystems). 
